BioSpace News Archive

Instil Bio, Inc. today announced that company management will participate in an upcoming investor conference.

Iterum Therapeutics plc today announced the United States Patent and Trademark Office has issued the Company a Notice of Allowance for U.S. patent application number 16/972,300.

Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) today announced the commercial availability, beginning October 3, 2022, of CIMERLI™ (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all approved indications.

Zucara Therapeutics Inc., today announced that its positive proof-of-concept data has enabled the Company to secure continued funding for a Phase 2 clinical study of ZT-01, which is expected to begin in Q1 2023.

Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, today announced a $33.4 million expansion of its Series A financing, bringing the total investment in Naveris to $51 million.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), announced the presentation of new findings on the burden of hyperphagia and obesity on patients with Bardet-Biedl syndrome (BBS) and their caregivers during the 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE 2022) held in Rome on Sept. 15 to 17.

Access Vascular, Inc. announced the outcome of a peer-reviewed study published in the Journal of Infusion Nursing that demonstrated a significant reduction in complications when using AVI’s consistently hydrophilic midline catheters.

Ventyx Biosciences, Inc. announced today that it has entered into a stock purchase agreement for the sale of 5,350,000 shares of its common stock at an offering price of $33.00 per share.

AmyriAD Therapeutics today announced that it will host a key opinion leader (KOL) webinar, entitled, “ Looking Beyond Amyloid for Alzheimer’s Disease.

Viracta Therapeutics’ Board of Directors appoints Mark Rothera as President and Chief Executive Officer.